Common Mutants found in COVID-19 and variant line
Most U.S. doctors have no way to determine which variant of the coronavirus a patient is carrying, a distinction that could mean the difference between life and death. High-risk patients carrying the Delta variant could benefit greatly from two particular monoclonal antibody treatments shown to reduce hospitalization and death. But those medications would most likely do nothing for patients with Omicron, who would only respond to a third antibody treatment that is in very short supply.
Delta patients benefit most from the antibody drugs made by Regeneron (casirivimab and imdevimab) and Eli Lilly (Bamlanivimab), while Omicron patients benefit from antibodies from GlaxoSmithKline and Vir Biotechnology (sotrovimab (VIR-7831)).
We have the “GG Omicron/Delta PCR kit” product (Approved for use in Europe/Asia per CE/ISO and NOT AUTHORIZED OR CLEARED FOR USE IN THE USA) made from a ISO 13485 certified facility. “GG COVID-19 Omicron and Delta kit” (Cellgenemedix, USA) is a cost effective diagnostic tool optimized for rapid (90 minutes from RNA extraction to results) POC diagnosis of Omicron and Delta as well as SARS CoV-2 infection. We have validated this product in hundreds of clinical Omicron specimens.
Accurate diagnosis of SARS-CoV-2 as well as differentiation of Delta and Omicron variants is crucial in the decision making of high risk patients, especially when deciding whether they should be considered for in-patient care versus outpatient follow-up. GG COVID-19 Omicron and Delta kit (UNAVAILABLE in USA, CE MARK and AVAILABLE for sale in Asia and EUROPE)is a cost effective diagnostic tool optimized for rapid (90 minutes from RNA extraction to results) POC diagnosis of Omicron and Delta as well as SARS CoV-2 infection.
While it is screening for the variants and cannot replace sequencing as far as accuracy, the analytical sensitivity and specificity is high in our studies and the cost of this test is known to be similar to or slightly more expensive than the previous Real Time RT-PCR test for diagnosis of COVID-19. Also, the ability to screen tens of thousands of patients per lab in one setting is something that sequencing can never do, but real-time PCR can do.